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Abstract 
Phosphatidylethanol species (PEths) are promising biomarkers of alcohol consumption. Here 
we report on the set-up, validation and application of a novel UHPLC-ESI-MS/MS method 
for the quantification of PEth 16:0/18:1, PEth 18:1/18:1, and PEth 16:0/16:0 in whole blood 
(30 µL) and in venous (V, 30 µL) or capillary (C, 3 punches (3 mm)) dried blood spots 
(DBS). The methods were linear from 10 (LLOQ) to 2000 ng/mL for PEth 16:0/18:1, from 10 
(LLOQ) to 1940 ng/mL for PEth 18:1/18:1, and from 19 (LLOQ) to 3872 ng/mL for PEth 
16:0/16:0. Extraction efficiencies were higher than 55% (RSD<18%) and matrix effects 
compensated by IS were between 77 and 125% (RSD<10%). Accuracy, repeatability and 
intermediate precision fulfilled acceptance criteria (bias and RSD below 13%). Validity of the 
procedure for determination of PEth 16:0/18:1 in blood was demonstrated by the successful 
participation to a proficiency test. The quantification of PEths in C-DBS was not significantly 
influenced by the hematocrit, punch localization or spot volume. The stability of PEths in V-
DBS stored at room temperature was demonstrated up to 6 months. The method was applied 
to authentic samples (whole blood, V-DBS and C-DBS) from 50 inpatients in alcohol 
withdrawal and 50 control volunteers. Applying a cut-off value to detect inpatients at 221 
ng/mL for PEth 16:0/18:1 provided no false positive results and a good sensitivity (86%). 
Comparison of quantitative results (Bland-Altman plot, Passing-Bablok regression and 
Wilcoxon signed rank test) revealed that V-DBS and C-DBS are valid alternatives to venous 
blood for the detection of alcohol consumption.  
 
Introduction 
Phosphatidylethanols (PEths) are a group of abnormal phospholipids formed by the presence 
of ethanol in cell membranes [1]. They are biomarkers of alcohol consumption [2] present in 
blood, mainly located in erythrocytes [3], and in different organs [4]. Up to forty-eight 
different PEths have been detected in blood collected in autopsy cases of heavy drinkers [5]. 
All PEths have a common phosphoethanol head on which two fatty acid chains of variable 
length and degree of saturation are attached. Although blood analysis from heavy drinkers 
shows inter-individual variations of the distribution of the different PEths [6], the 
predominant species in blood after alcohol consumption are PEth 16:0/18:1 (30-46%) and 
PEth 16:0/18:2 (16-28%) [5-9]. Other PEths detected are PEth 18:1/18:1 and PEth 18:0/18:2 
(identical molecular masses), together accounting for about 11-12% of total PEths [6, 7] while 
PEth 16:0/16:0 accounts for about 5% [6]. The half-life of PEths in whole blood was 
calculated to be 4.0 ± 0.7 days [3]. In case of chronic/excessive alcohol consumption, PEths 
are detectable in blood up to 28 days after sobriety [10]. Moreover, quantification of PEths 
can be used to detect the degree of alcohol consumption as a significant correlation between 
the PEths concentrations in blood and the amount of consumed ethanol has been demonstrated 
[11].  
Numerous studies have been published on the quantification of PEths in blood and these have 
been reviewed in 2012 [10]. The most used extraction technique is a liquid-liquid extraction 
(LLE) with hexane [5-7, 11-17] (or heptane [8]) after stepwise addition of blood to 
isopropanol and the internal standard (IS) solution. Some methods added water [6], borate 
buffer pH 9 [5] or sodium acetate buffer pH 5 [15] to dilute the blood. Some publications 
reported other types of sample preparation, such as protein precipitation with methanol [18] or 
protein precipitation followed by an online-solid phase extraction [19]. A number of detection 
methods is based on HPLC with normal phase columns coupled to light-scattering detection 
(ELSD); chromatography has been carried out with hexane and propanol-based gradients 
containing acetic acid and triethylamine [3, 4, 11, 12]. Quantification limits (LLOQ) obtained 
with these methods ranged between 100–500 ng/mL [4, 11], analysing 250 to 300 µL of 
whole blood. PEths have also been analysed with non-aqueous capillary electrophoresis (CE) 
coupled to UV [13] detection. Both HPLC-ELSD and CE-UV [13] methods measure the total 
amount of PEths. However, LC methods coupled to MS/MS detection allow to obtain much 
lower LLOQs (between 0.7 and 83 ng/mL, based on the analysis of between 100 and 300 µL 
of whole blood) and are able to identify and quantify individual molecular species [6-8, 15, 
18-20].   
To improve the stability of compounds in whole blood and to facilitate the storage and 
transportation of samples [21], DBS methods have been developed. Numerous DBS-based 
methods have been published for a wide variety of applications, including therapeutic drug 
monitoring and toxicology [22]. Also alcohol markers such as ethyl glucuronide, ethyl 
sulphate and PEths have been determined, starting from DBS ([15, 18, 21, 23-25]; reviewed 
by Sadones et al, 2014 [26]). Since 2011, two publications have reported on the quantification 
of PEth 16:0/18:1 [15, 18] and PEth 18:1/18:1 [15] in V-DBS samples, while only one [21] 
reported on the analysis of C-DBS samples (detection of PEth 16:0/18:1 in newborns to detect 
prenatal alcohol exposure). V-DBS are prepared by spotting a fixed volume of venous blood 
onto a filter paper, whereas C-DBS are generated by direct collection of blood drops 
appearing after a finger or heel prick onto a filter paper. C-DBS offer the advantage compared 
to venipuncture of being less invasive and not requiring the service of nurses or physicians. 
Since these are typically collected in a non-volumetric way, these samples are mostly 
processed by excising punches with a fixed diameter from the global spot. This partial-spot 
approach requires the assessment of the impact of variables such as hematocrit, punch 
localization and spot volume on the quantitative result [27, 28].  
In this paper, we present the validation of UHPLC-ESI-MS/MS methods for the quantification 
of the 3 PEths (PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0) in whole blood, V-DBS 
and C-DBS according to international guidelines [29] and published recommendations [27]. 
To our knowledge, this is the first report on the rigorous validation of the differences between 
capillary and venous DBS including the impact of specific parameters such as the influence of 
hematocrit, punch localization and spot volume on PEths. In addition, a sensitive method for 
PEth 16:0/16:0 in DBSs was developed and stability of the three species in V-DBS was 
evaluated over a period of 6 months. Moreover, successful participation to a proficiency test 
demonstrated the validity of the method for blood (no proficiency tests for DBS are 
available). Finally, the developed methods were applied to evaluate the agreement between 
the quantitative results from the analysis of whole blood, V-DBS and C-DBS obtained from 
100 volunteers (inpatients in alcohol withdrawal and control volunteers). Receiver operating 
characteristic (ROC) curves performed on these results allow us to propose a possible cut-off 
value to detect chronic and excessive alcohol consumption. It was our main objective to 
investigate whether C-DBS could be a reliable alternative for the detection of PEths in whole 
blood, as this could lead to a more user friendly and practical approach to detect excessive and 
chronic alcohol consumption.   
 
Materials and Methods 
Chemicals 
1,2-dioleoyl-sn-glycero-3-phosphoethanol (sodium salt; PEth 18:1/18:1), 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanol (sodium salt; PEth 16:0/16:0) were obtained from Avanti Polar 
Lipids  (Alabaster, Alabama, USA). Palmitoyl-2-oleoyl-sn-glycero-3 phosphoethanol (PEth 
16:0/18:1) was purchased from Enzo Life Sciences (Antwerp, Belgium). As deuterated 
analogues have not been commercialised yet, four different internal standards from Avanti 
Polar Lipids were evaluated during validation: 1,2-dipalmitoyl-sn-glycero-3-
phosphomethanol (sodium salt; PMeth 16:0/16:0; IS), 1,2-dioleoyl-sn-glycero-3-
phosphomethanol (sodium salt; PMeth 18:1/18:1; IS), 1,2-dipalmitoyl-sn-glycero-3-
phosphopropanol (sodium salt; PProp 16:0/16:0; IS) and 1,2-dioleoyl-sn-glycero-3-
phosphopropanol (sodium salt; PProp 18:1/18:1; IS). 
Isopropanol (ULC/MS), tetrahydrofuran (ULC/MS), ammonium acetate (ULC/MS), water 
(HPLC) and methanol (ULC/MS) were purchased from Biosolve (Valkenswaard, The 
Netherlands). Isopropanol and n-hexane, gradient grade for liquid chromatography, were 
purchased from Merck KGaA (Darmstadt, Germany). Formic acid for mass spectrometry 
(~98%) was purchased from Sigma-Aldrich (Steinheim, Germany).  
 
Standard solutions, calibrators and quality control (QC) samples  
Stock solutions of PEths (PEth 16:0/18:1 (1.000 mg/mL), PEth 18:1/18:1 (0.970 mg/mL) and 
PEth 16:0/16:0 (0.968 mg/mL)) and stock solutions of the 4 evaluated ISs (PMeth 16:0/16:0 
(0.968 mg/mL), PMeth 18:1/18:1 (0.971 mg/mL), PProp 16:0/16:0 (0.969 mg/mL) and PProp 
18:1/18:1 (0.971 mg/mL)) were prepared in methanol. A calibrator working solution (100 
µg/mL), a QC working solution (50 µg/mL) and an IS working solution (5 µg/mL) for the 
blood and V-DBS methods were prepared by diluting the stock solutions in methanol. For the 
C-DBS method, a calibrator working solution of 250 µg/mL, a QC working solution of 250 
µg/mL and an IS working solution of 0.25 µg/mL were prepared in methanol. All working 
solutions were stored at -18°C. 
Daily dilutions of IS working solutions were performed in solution A, consisting of 
isopropanol, 10 mM ammonium acetate buffer and formic acid (6:4:0.2, v/v), to reach a 
concentration of 100 ng/mL (used for the whole blood and V-DBS method) and 10 ng/mL 
(used for the C-DBS method). 
Daily dilutions of calibrator working solutions and QC working solutions were performed in 
water to obtain 8 different concentrations for calibrators and 3 for QCs. A second dilution was 
performed in EDTA blank whole blood (ESM Tables S1 and S2). Final calibrator 
concentrations in blood were between 10 and 2000 ng/mL for PEth 16:0/18:1, 10 and 1940 
ng/mL for PEth 18:1/18:1 and between 19 and 3872 ng/mL for PEth 16:0/16:0. For the two 
DBS methods, 30 µL of calibrators and QCs in blood were spotted onto Whatman 903 filter 
paper (GE Healthcare). Spots were dried for minimum 2 hours at room temperature. The 
complete DBS was used for the V-DBS method and 3 punches (3 mm) were used for the C-
DBS method, unless indicated otherwise. Here, we typically used 3 punches from the same 
DBS, except in the application study, where not from all C-DBS three 3-mm punches could 
be obtained. The hematocrit of the blood used to prepare the DBS calibrators was 0.48 ± 0.02, 
as measured using a Sysmex XP-300™ automated hematology analyzer (Sysmex America, 
Inc.). 
 
Sample preparation 
PEths were extracted by LLE with n-hexane. For the whole blood method, 30 µL of the 
sample was added to a 5 mL disposable glass tube containing 250 µL of solution A 
(consisting of isopropanol, 10 mM ammonium acetate buffer and formic acid (6:4:0.2, v/v)) 
and 50 µL of the IS solution (100 ng/mL). After a quick mixing (vortex), 1 mL n-hexane was 
added and the sample was gently mixed for 10 minutes. The tubes were centrifuged (10 min, 
14’000 rpm (20’800 x g), 4°C) and the clear supernatant was transferred to a total recovery 
glass vial (Waters, Zellik, Belgium) and evaporated to dryness during 30 minutes in a 
rotational vacuum concentrator (RVC 2-33 IR, Martin Christ, Osterode am Harz, Germany). 
The final dried extract was dissolved in 250 µL of a solution B (50% of mobile phase A and 
50% of mobile phase B, see below).  
For the V-DBS method, the complete DBS (30 µL) was excised and placed in a 5 mL 
disposable glass tube containing 250 µL of solution A and 50 µL of the IS solution (100 
ng/mL). For the C-DBS method, three (or one, where indicated) punches (3 mm) were excised 
from the DBS and placed in a 5 mL disposable glass tube containing 250 µL of solution A 
and 50 µL of the IS solution (10 ng/mL). For both DBS methods, the tubes were gently mixed 
for 1 hour. After adding 1 mL of n-hexane, the samples were mixed for another 10 minutes. 
After centrifugation, the clear supernatant was transferred in total recovery glass vials and 
evaporated to dryness. The final dried extract was dissolved in 250 µL of solution B for the 
V-DBS and in 100 µL of solution B for the C-DBS. 
For the whole blood method and the V-DBS method, 5 µL was injected in partial loop with 
needle overfill mode. For the C-DBS method, 10 µL was injected in full loop mode.  
 
Liquid chromatographic and mass spectrometric conditions 
Analyses were performed on an Aquity UPLC
® 
system coupled to a Xevo TQ S tandem mass 
spectrometer (Waters, Manchester, UK) equipped with an electrospray ionization source 
operated in negative mode. The compounds were separated on an Acquity UPLC
®
 BEH C8 
(2.1 x 50 mm, 1.7 m) column (Waters) using as mobile phase A 10 mM ammonium acetate 
buffer with 0.05% formic acid (pH 2) and as mobile phase B isopropanol with 10% of 
tetrahydrofuran at a flow rate of 400 L/min. The gradient elution started with 40% of mobile 
phase A and decreased to 0% of mobile phase A at 1.5 minutes. The washing step, containing 
100% of solution B, was held for 1 minute and was followed by 1 minute re-equilibration 
with the starting condition, resulting in a total run time of 3.5 minutes. The column 
temperature was set at 60°C.  
For the MS/MS detection, the following parameters were used: temperature of source gas 
(nitrogen) was 150°C, desolvatation gas (nitrogen) flow was 1000 L/h at 650°C, capillary 
voltage was 3 KV, cone voltage was 10 V with a cone gas flow at 150 L/h and collision gas 
(argon) flow was 0.15 mL/min. Detection was performed in the multiple reaction monitoring 
mode (MRM). Two transitions were measured for PEths, one for the quantification 
(underlined in the text) and one for the qualification. For ISs only one MRM transition was 
used. The dwell time was fixed at 17 msec and the following precursor/product ion transitions 
(cone voltage, collision energy) were selected: 701.53/255.33 (10 V, 35 V), 701.53/124.98 
(10 V, 40 V) for PEth 16:0/18:1, 727.62/281.22 (10 V, 35 V), 727.62/463.22 (10 V, 25 V) for 
PEth 18:1/18:1, 675.56/255.19 (10 V, 30 V), 675.56/124.97 (10 V, 35 V) for PEth 16:0/16:0, 
741.63/281.27 (20 V, 35 V) for PProp 18:1/18:1, 689.55/255.15 (20 V, 30 V) for PProp 
16:0/16:0, 713.57/281.27 (20 V, 30 V) for PMeth 18:1/18:1 and 661.50/255.27 (10 V, 30 V) 
for PMeth 16:0/16:0. 
 
Method validation 
Selectivity, sensitivity, matrix effect, extraction efficiency, limit of quantification, linearity, 
accuracy and stability were evaluated based upon international guidelines [29]. The influence 
of hematocrit, punch localization and spot volume were evaluated for the C-DBS method [27, 
28]. 
To study endogenous interferences, six blank whole blood samples from different teetotallers 
were analysed. To verify that IS compounds do not interact with PEths, two zero samples 
(blank samples spiked with IS solution) were analysed. According to the EMA guideline, in 
our method interferences are acceptable as long as the signal was lower than 20% of the 
response at the LLOQ [30].  
Matrix effect was quantified and evaluated by the post-extraction addition technique using six 
different blank bloods from teetotallers [31]. Whole blood (30 µL), V-DBS (complete 30 µL 
DBS) and C-DBS (3 filter paper punches spiked each with 3.5 µL of whole blood) were 
extracted. The reference standards and IS (diluted in the mobile phase) were added in the total 
recovery vial before the injection. These samples were compared with control samples spiked 
at the same theoretical concentration in the mobile phase. Extraction efficiency was evaluated 
by comparing responses of six blank samples spiked before sample preparation with 
responses of six blank samples, where the reference standards were spiked after the sample 
preparation in the mobile phase. Matrix effect and extraction efficiency were evaluated at low, 
medium and high concentrations. For the C-DBS method, blood samples with varying 
hematocrit levels (measured from 0.31 to 0.58) were used, to study the influence of the 
hematocrit variation on the extraction efficiency and on the matrix effect.  
The lower limit of quantification (LLOQ) is the lowest concentration of analyte with a signal-
to-noise ratio greater than 10/1 for both transitions and for which the bias and precision 
deviation is less than 20%.  
Calibration model and weighting factor were evaluated for each compound and each method. 
The linearity was tested by performing F-Tests (α=0.05). Homoscedasticity was tested 
visually by plotting residuals vs. fitted value. In case of heteroscedasticity, a weighted 
regression (1/x and 1/x
2
) was applied (slope and intercept). The sum of relative errors 
(difference between the calculated concentration and its nominal concentration) for each 
model was calculated and plotted against the nominal concentrations. The model with a R
2
 ≥ 
0.99 with the lowest sum of relative errors was selected. The goodness of fit of the selected 
model was tested, calculating the relative errors for calibrators and QCs. The relative errors 
should be lower than 15% except for the LLOQ (< 20%) [30].  
Three internal QCs spiked at low, medium and high concentration, were analysed in duplicate 
on 8 different days to assess accuracy (bias) and precision (repeatability and intermediate 
precision). A single factor ANOVA test with significance level (α) of 0.05 allows calculating 
bias, repeatability and intermediate precision with these data, with acceptance criteria of 15% 
(20% for the LLOQ). The measurement uncertainty was also calculated (2.12*RSDt) and used 
to interpret quantitative results close to the LLOQ or close to the cut-off value.    
The validity of the PEth 16:0/18:1 quantification in blood was tested by participation to a 
proficiency test organized by Equalis (Uppsala, Sweden). 
Processed sample stability and long term storage stability were evaluated at low and high 
concentrations for the whole blood method and for the V-DBS method. The mean response of 
the stability samples should be within 90 – 110% of the mean response of the control samples 
and the 90% confidence interval of the stability sample responses should be within ± 20% of 
the control sample responses. 
The influence of the hematocrit on the response was evaluated for five hematocrit values at 
low and high concentrations. Blank blood samples with variable hematocrit level were 
prepared by adding or removing plasma to EDTA blank blood samples. The measured 
hematocrit values were 0.39, 0.42, 0.48, 0.50 and 0.57. Six spots per concentration and per 
hematocrit level were prepared and single centrally located punches were analysed. Measured 
responses were compared with a One-way ANOVA test (α=0.05). To evaluate whether no 
artefactual results were obtained because spiked samples might behave differently from real 
samples (where PEth species are presumably located in erythrocytes), we set up an 
experiment in which blood with different hematocrit was prepared from blood of two 
inpatients. More specifically, 200 µL of blood of an inpatient was diluted with plasma 
(between 25 and 200 µL) and erythrocytes (between 0 and 175 µL) of an alcohol abstainer to 
generate 6 blood samples of 400 L with a different hematocrit (with measured hematocrits 
between 0.20 and 0.60) but with the same PEths concentrations (PEths virtually exclusively 
being derived from the 200 L of inpatient blood). This blood was used to generate DBS, 
which were processed as real samples (see sample preparation section). The DBS analysis 
was performed in quadruplicate at each hematocrit level. Also the blood PEths concentrations 
were determined and served as a reference. 
The influence of the punch localization (peripherally or centrally) was evaluated at low and 
high concentrations and at low (0.39), intermediate (0.48) and high (0.57) hematocrit levels. 
Six spots per concentration and per hematocrit level were prepared and the responses 
measured in peripherally and centrally located punches (one central and one peripheral punch 
were analyzed per DBS) were compared using a One-way ANOVA test (α=0.05).  
Three blood spot volumes (20, 35, 50 µL) were tested at low (0.32), intermediate (0.48) and 
high (0.67) hematocrit levels and at 2 concentrations; low and high. Six spots per 
concentration and per hematocrit level were prepared and centrally located 3 mm punches 
(1/DBS) were analysed. Responses were compared using a One-way ANOVA test (α=0.05) to 
detect significant differences.  
The normality of the distributions and the homogeneity of variances were tested using the 
Shapiro-Wilk test and the Levene’s test prior to One-way ANOVA tests [32].  
 
Application to a comparative study  
Sample collection 
Whole blood and C-DBS from inpatients in alcohol withdrawal were collected at the 
Brugmann Hospital (Brussels, Belgium) one business day after their admission. Whole blood 
and C-DBS from control volunteers were collected by the medical staff of the Military 
Hospital in Brussels (Belgium). The inpatients group was composed of 37 males and 13 
females, between 27 and 71 years (mean = 47, median = 47) and with a self-reported number 
of abstinence days before the sampling between 1 and 21 (mean = 4, median = 2). The control 
group was composed of 23 males and 27 females, between 22 and 64 years (mean = 40, 
median = 37) and with a self-reported mean alcohol consumption per week between 0 and 16 
units (mean = 5, median = 6). Seven out of the 50 control volunteers were teetotallers.         
Venous whole blood samples were collected in a 4 mL EDTA tube and were stored at -80°C 
until analysis. Five C-DBS were collected onto a Whatman 903 filter paper card after a 
fingertip prick with a contact-activated lancet (BD Microtainer®, Becton Dickinson). Five V-
DBS were prepared from the EDTA tubes by pipetting 30 µL of venous blood onto a filter 
paper. C-DBS and V-DBS were left to dry for minimum 2 hours at room temperature and 
were then stored in zip-closure plastic bags containing a desiccant packet (Sigma-Aldrich) at 
room temperature until the analysis.  
The study protocol was approved by the ethics committee of the Brugmann Hospital 
(Brussels, Belgium) and informed consent was obtained from each subject before enrolment 
in the study (B077201420445). 
 
Statistical analysis 
Bland-Altman plot, Passing-Bablok regression analysis and Wilcoxon signed rank test were 
used to study the agreement between quantitative results obtained from whole blood, V-DBS 
and C-DBS samples [33]. A Bland-Altman plot is used to assess the absence of systematic 
differences between two measurements. The mean of the two measurements is plotted against 
the difference between these, 95% of the differences are expected to lie within the limits of 
agreement (mean ± 1.96 SD). The Passing-Bablok regression analysis is a scatter diagram of 
the concentrations obtained with two different methods. The regression line and equation are 
used to detect measurement errors. No proportional differences are observed as long as the 
95% confidence interval of the slope includes 1 and no systematic differences are observed as 
long as the 95% confidence interval of the intercept includes the zero value. Wilcoxon signed 
rank test was performed to detect significant differences (p-value<0.05) between the 
concentrations obtained from two methods.  
ROC curve analyses were performed to determine optimal cut-off values (higher sensitivity 
with 0 false positive results) to distinguish between inpatients in alcohol withdrawal and 
control volunteers. The area under the curve (AUROC) was used to quantify the overall 
ability of the method to discriminate between the two populations. A perfect diagnostic 
method (0 false positives and 0 false negatives) will have an area of 1, where a method with 
no diagnostic ability will have an area of 0.5.     
Results  
 
Method Validation 
Linearity, LLOQ, matrix effects, extraction efficiency, selectivity, sensitivity and accuracy 
were assessed for the three methods. Stability was tested for the whole blood and V-DBS 
methods. For the C-DBS method, the impact of hematocrit, punch localization and blood spot 
volume were evaluated.  
The linear (1/x) calibration curves ranged from 10 (LLOQ) to 2000 ng/mL for PEth 16:0/18:1, 
from 10 (LLOQ) to 1940 ng/mL for PEth 18:1/18:1 and from 19 (LLOQ) to 3872 ng/mL for 
PEth 16:0/16:0.  
The non-IS-compensated matrix effect was between 68 and 137% (RSD<20%) for PEth 
16:0/18:1, between 73 and 121% (RSD<12%) for PEth 18:1/18:1 and between 59 and 110% 
(RSD<20%) for PEth 16:0/16:0. For the three PEths, PMeth 18:1/18:1 was selected as IS, 
because it better compensated for matrix effect than PMeth 16:0/16:0 and PProp 18:1/18:1 
(Table 1) and had a better peak shape compared to PProp 16:0/16:0. The matrix effect 
compensated by this IS was between 77 and 125% (RSD<10%) for all PEths. Visual 
inspection of the results indicated no influence of the hematocrit level on matrix effect for the 
C-DBS method.  
 
Table 1  Matrix effect and matrix effect compensated with PMeth 18:1/18:1, PMeth 16:0/16:0, PProp 18:1/18:1 
and PProp 16:0/16:0 in whole blood. Matrix effect and matrix effect compensated with PMeth 18:1/18:1 in V-
DBS and C-DBS.  
 
Results for the extraction efficiency, repeatability, intermediate precision and bias are 
reported in Table 2.  
 
Table 2 Validation results for PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0 in blood, V-DBS and C-DBS. 
L = low QC, M = medium QC, H = high QC.   
 
In summary, no interfering peaks were detected in blank samples and the addition of the IS 
did not interfere with PEths detection. The recovery was between 66 and 100% (RSD<18%) 
for the blood method, between 55 and 63% (RSD<14%) for the V-DBS method and between 
61 and 78% (RSD<15%) for the C-DBS method. Visual inspection of the results indicated no 
influence of the hematocrit level on extraction efficiency (Fig. 1).  
 Fig. 1 Extraction efficiency % for PEths from DBS at three concentrations (low, medium and high) and prepared 
from 6 whole blood samples with varying hematocrit levels.   
 
 
The bias (%), repeatability (%RSDr) and intermediate precision (%RSDt) were less than 13% 
for whole blood, V-DBS and C-DBS methods. The maximal uncertainties of measurement 
(2.12*RSDt) were 23% (blood), 25% (V-DBS) and 24% (C-DBS) for PEth 18:1/16:0; 25% 
(blood), 22% (V-DBS) and 23% (C-DBS) for PEth 18:1/18:1 and 22% (blood, C-DBS) and 
21% (V-DBS) for PEth 16:0/16:0.  
The validity of the quantification of PEth 16:0/18:1 in blood was demonstrated by the 
successful participation (z-score<2) to a proficiency test. The z-score obtained ((reported 
value – target value) / SD) was 0.11 for sample B (reported value = 2.52 µmol/L, target value 
= 2.50 µmol/L, SD=0.23, N=8) and 1.43 for sample C (reported value = 0.17 µmol/L, target 
value = 0.16 µmol/L, SD=0.01, N=8). The samples were used to create V-DBS and z-scores 
of 0.38 for sample B (measured value = 2.59 µmol/L) and 0.22 for sample C (measured value 
= 0.16 µmol/L) were calculated ((measured value – target value) / SD). PEths were not 
detected in sample A (reported value < LLOQ). Sample A was whole blood from a teetotaller.  
All samples were stable in the autosampler for 72 h. PEths were stable up to 6 months when 
stored at -80° C in EDTA tubes. PEth 16:0/18:1 and PEth 18:1/18:1 were stable during 6 
months in V-DBS samples stored at room temperature in zip-closure plastic bags containing a 
desiccant packet. The 90% confidence interval of the stability sample responses for PEth 
16:0/16:0 in V-DBS were within ± 20% of the control sample responses, although the mean 
response of the high stability samples was 119% of the mean response of the control samples.   
No significant differences (p>0.05) were observed between the mean responses obtained for 
the analysis of V-DBS samples spiked with PEths reference standard, prepared from blood 
with hematocrit levels spanning a normal to high range (0.39, 0.42, 0.48, 0.50, 0.57). In 
addition, varying the hematocrit level (between 0.20 and 0.60) of real inpatients’ blood 
samples (by adding blank plasma and red blood cells) did not adversely affect quantification, 
as demonstrated in Fig. 2, which depicts the bias when comparing results obtained from DBS 
with those obtained from blood. Similar mean responses were obtained from 20, 35, 50 µL V-
DBS samples. Finally, a one-way ANOVA test showed no significant differences between 
mean responses obtained with peripherally and centrally located punches. The influence of 
hematocrit and volume spotted on PEths responses are presented in ESM Fig. S1.  
 Fig. 2 Influence of the hematocrit on PEths quantification in real positive samples (3 punches excised from DBS 
created from the blood of inpatients in alcohol withdrawal). Results, with standard deviation (RSD%), are 
presented for each haematocrit level as mean % bias (N=4) compared with the reference value measured in 
whole blood. The mean measured blood concentrations for PEth 16:0:18:1, PEth 18:1/18:1 and PEth 16:0/16:0 
were 728, 52 and 89 ng/mL for inpatient 1 and 659, 46 and 100 ng/mL for inpatient 2, respectively.  
 
Comparative study  
Whole blood, V-DBS and C-DBS from inpatients in alcohol withdrawal (N=50) and control 
volunteers (N=50) were analysed to quantify PEth 16:0/18:1, PEth 18:1/18:1 and PEth 
16:0/16:0. For the C-DBS method, the 3 punches analysed were excised either from the same 
spot (15% of the cases), from two different spots (30% of the cases) or from three different 
spots (55% of the cases).  
Concentrations measured in whole blood, V-DBS and C-DBS from all study participants were 
compared using Bland-Altman plot, Passing-Bablok regression analysis and Wilcoxon signed 
rank test. 
PEth 16:0/18:1 was quantified (>LLOQ) in 50/50 inpatients and in 18/50 control volunteers. 
Concentrations measured in blood ranged from 16 to more than 2000 ng/mL (mean = 1232, 
median = 1087) in alcoholics and were between 13 and 220 ng/mL (mean = 59, median = 49) 
in control volunteers with a quantifiable result. PEth 18:1/18:1, with blood concentrations 
ranging from 17 to 307 ng/mL (mean = 101, median = 78), was measured in 47/50 inpatients 
and in 1/50 control volunteers (17 ng/mL). PEth 16:0/16:0 was quantified only in some 
inpatient samples (34/50) with concentrations varying from 25 to 203 ng/mL (mean = 97, 
median = 89). An overview is given in Figs. 4 and 5. 
In the comparison of the results obtained from blood, C-DBS and V-DBS, correlation 
coefficients exceeded 0.995 for PEth 16:0/18:1 (N=68), 0.978 for PEth 18:1/18:1 (N=48) and 
0.962 for PEth 16:0/16:0 (N=32). As shown in Fig. 3 (Right) and reported in Table 3 
(presenting the numerical results), the mean % differences in the concentration between 
venous blood and C-DBS included the 0 value for the three PEths. The 95% confidence 
intervals of the slope obtained from the Passing-Bablok regression analysis included or were 
very close to 1 and the 95% confidence intervals of the intercept included the 0 value (Fig. 3, 
Left and Table 3). No significant differences (p≥0.05) in the mean measured concentrations 
were detected using Wilcoxon signed rank test. The same comparisons were performed 
between blood and V-DBS and between V-DBS and C-DBS for the three compounds (Table 
3 and ESM Figs. S2 and S3), with essentially the same conclusions. Only in 3 cases with 
measurable (i.e. above LLOQ) PEth 16:0/16:0 in whole blood, V-DBS and C-DBS, a 
discrepancy was observed, when taking into account the measurement uncertainty at the 
LLOQ. The blood, V-DBS and C-DBS concentrations in these 3 cases were respectively 32, 
23* and 25 ng/mL (case 1), 22*, 31 and 21* ng/mL (case 2) and 27, 29 and 22* ng/mL (case 
3). For 4 quantitative results (indicated with an asterisk) in these 3 cases, the results should 
actually be considered negative when the measurement uncertainty is taken into account 
(exemplified in ESM Fig. S4). These three cases were not taken into account for the statistical 
analysis. 
 
Fig. 3 (Left) Passing-Bablok regression analyses of PEths concentrations measured in blood and in C-DBS. The 
identity line is indicated using a dotted line. (Right) Bland-Altman analyses of PEths plotting the % difference 
between blood and C-DBS concentrations. The average difference is represented by a solid line, the limits of 
agreement (1.96 SD) by dashed lines. The 95% confidence intervals for the mean and the limits of agreement are 
shown with dotted lines. 
  
Table 3 Results obtained for the Passing-Bablok analysis, Bland-Altman analysis and Wilcoxon signed rank test 
performed on PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0 to compare Blood vs. C-DBS, Blood vs. V-
DBS and V-DBS vs. C-DBS. N = number of positive results (above LLOQ + uncertainty), CI = confidence 
interval. * 3 samples were in disagreement concerning the detection or no detection of PEth 16:0/16:0 when 
analysed in blood, V-DBS and C-DBS. These samples were not used in the statistical analysis. 
 
 
Distributions of the concentrations of PEth 16:0/18:1 measured in whole blood, V-DBS and 
C-DBS from inpatients in alcohol withdrawal and control volunteers are presented in Fig. 4. 
 
Fig. 4 Distribution of the PEth 16:0/18:1 concentrations measured in blood, V-DBS and C-DBS of patients in 
alcohol withdrawal (N=50) and in control volunteers (N=18). The box represents the values between the lower 
and upper quartile and the middle line represents the median. The whiskers represent the extremes value, 
excluding outliers (represented by dots). The indicated area (below) is enlarged (right above). 
 
ROC analysis was performed to determine a cut-off value to distinguish between control 
volunteers and inpatients in alcohol withdrawal using the concentration of PEth 16:0/18:1 in 
blood. A cut-off value at 221 ng/mL (AUROC=0.947) for PEth 16:0/18:1 provided no false 
positive results (1-specificity=0) and a sensitivity of 0.86 (7 out of 50 inpatients were 
classified as social drinkers). Application of this cut-off for C-DBS and V-DBS yielded 
exactly the same result, lending further support to the validity of the approach of using DBS. 
 Fig. 5 Number of blood samples with a measured concentration above LLOQ (+ uncertainty) of PEth 16:0/18:1, 
PEth 18:1/18:1 and PEth 16:0/16:0 and above the cut-off (+ uncertainty) for PEth 16:0/18:1. For the uncertainty 
at the cut-off, the uncertainty established at the LLOQ was used. 
 
 
Discussion 
 
UHPLC-ESI-MS/MS methods for the quantification of PEths in whole blood, V-DBS and C-
DBS have been developed and validated using international guidelines [29] and published 
recommendations [27]. PEth 16:0/18:1 and PEth 16:0/18:2 are the two predominant PEths 
detected in blood after alcohol consumption. Taking into account the commercial availability 
of the PEths standards at the moment, the methods presented in this paper have been 
developed for PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0. As deuterated analogues 
have not been commercialised yet, four different ISs (PMeth 16:0/16:0, PMeth 18:1/18:1, 
PProp 16:0/16:0 and PProp 18:1/18:1) were evaluated during validation. In this study, PMeth 
18:1/18:1 compensated best for matrix effect for each compound and was therefore chosen as 
IS for all 3 methods.  
The detection of PEths requires highly sensitive techniques, due to the low amount of a 
certain PEth present in the sample (e.g. 16:0/16:0) and/or due to a low amount of sample (e.g. 
C-DBS). Therefore, special attention was paid to decrease possible ion-suppression by 
optimizing both the extraction and the chromatographic separation. 
Variable recoveries, ranging from 33% (PEth 16:0/16:0 and PEth 16:0/18:1) [20] to 80% 
(PEth 16:0/16:0, PEth 18:1/16:0, PEth 18:1/18) [7], have been reported in past publications 
using a LLE with a mixture of isopropanol and hexane (2:3, v/v). We have optimised the LLE 
procedure to extract PEth from venous blood. Therefore, the pH during extraction was 
adjusted to 2 by adding 2% formic acid in a mixture of 10 mM ammonium acetate buffer and 
isopropanol before extraction with hexane. This resulted in a mean extraction efficiency from 
venous blood of 83% (RSD=13%) for PEth 16:0/18:1, 87% (RSD=13%) for PEth 18:1/18:1 
and 82% (RSD=20%) for PEth 16:0/16:0. Somewhat lower percentages were observed 
(between 55 and 78%) for the V-DBS and the C-DBS methods. Similar percentages, ranging 
from 68 to 91% [15] and 56 to 76% for PEth 16:0/18:1 [18] and from 27 and 43% for PEth 
18:1/18:1) [15], were reported earlier for other DBS-based methods. The basis for this 
somewhat lower extraction efficiency is not known. Interaction with the filter paper might be 
a possibility, as recently suggested by Koster et al. for immunosuppressants [34].   
Reversed phase LC separation is the method of choice for the identification and quantification 
of phosphatidylethanol species. The retention is based on the lipophilicity, determined by the 
length and number of double bonds present in the fatty acid side chains [35]. Because the 
nonpolar part of PEths tends to interact very strongly with the nonpolar hydrocarbon phase of 
a reversed phase column, the use of a more polar phase (i.e. C8 [14, 18, 20], C4 [7, 15] or 
phenyl [16]) instead of a C18 phase allows to decrease the retention of PEths [14]. The use of 
less polar solvents, such as tetrahydrofuran (index polarity = 4.0), isopropanol (index polarity 
= 3.9) or methanol (index polarity = 5.1) instead of acetonitrile (index polarity = 5.8) also 
improved the elution of PEths using a reversed phase column. In our methods, gradient 
elution based on an ammonium acetate buffer and a mixture of 10% tetrahydrofuran in 
isopropanol on a 50-mm C8 column was chosen.  
Our three methods (blood, V-DBS and C-DBS) have a LLOQ of 10 ng/mL for PEth 16:0/18:1 
and PEth 18:1/18:1 and of 19 ng/mL for PEth 16:0/16:0. In literature, LC-MS/MS methods 
for PEths quantification in blood have reported LLOQs between 8 to 83 ng/mL for PEth 
16:0/18:1, between 0.7 to 73 ng/mL for PEth 18:1/18:1 and between 0.7 to 68 ng/mL for PEth 
16:0/16:0. While it seems at first sight that our method is less sensitive, the most sensitive 
method published [6] required 300 µL of blood while our methods use 30 µL of sample. 
Using a low sample volume, such as 30 µL, was necessary for development of the C-DBS 
method. Published methods about the validation of PEths in DBS have reported LLOQs of 8 
ng/mL (3x3mm punches from a 30 µL DBS) [18] and 87 ng/mL (100 µL DBS) [15] for PEth 
16:0/18:1 and of 23 ng/mL (100 µL DBS) for PEth 18:1/18:1 [15]. The DBS methods 
presented here provide comparable or lower LLOQs for PEth 16:0/18:1 and 18:1/18:1, and 
have included PEth 16:0/16:0. Furthermore, to our knowledge, no publication has already 
evaluated the influence of hematocrit, punch localization and spot volume on the 
quantification of PEths in DBS. One-way ANOVA tests did not reveal a significant influence 
(p>0.05) of these parameters on quantification of the evaluated PEths (ESM Fig. S1). In 
addition, no influence of the hematocrit on matrix effect and extraction efficiency was 
observed (Fig. 1) and quantification was not affected when comparing DBS and blood 
concentrations in real samples with a wide hematocrit range (Fig. 2).  
An important advantage of DBS compared with venous blood is the improvement of analyte 
stability, avoiding the degradation of PEths in venous blood not stored at -80°C [24] and the 
post-collection synthesis of PEths in samples exposed to ethanol [18]. Helander et al. have 
demonstrated that PEths were stable in venous blood, if stored at −80 °C, and this up to 14 
months [7]. A decrease of the concentration of PEth 18:1/18:1 (18%) and PEth 16:0/18:1 
(25%) has been described for EDTA whole blood samples stored at -20°C for 30 days [24]. 
Stability of PEth in DBS (at -20°C and 20°C) has been assessed up to 30 days by Faller et al. 
[24]. Our results confirm the stability of PEths in blood stored at -80°C and, more 
importantly, demonstrate that PEths were stable in DBS samples stored in zip-closure plastic 
bags containing a desiccant packet at room temperature for up to 6 months, although a slight 
bias (119%) was observed for PEth16:0/16:0 in the QC high.  
Finally, the successful participation (z-scores<1.43) to an international proficiency test 
organised by Equalis (Uppsala, Sweden) proved that the venous blood method for the 
quantification of PEth 16:0/18:1 is accurate. 
Hundred authentic samples (50 inpatients in alcohol withdrawal and 50 control volunteers) 
were analysed using our 3 methods. To ensure C-DBS method validity, the hematocrit level 
of inpatients in withdrawal therapy (N=48) was measured and ranged between 0.33 and 0.49 
(mean = 0.43, median = 0.44), with 83% (40/48) of the inpatient hematocrit levels lying 
within the reference range [28, 36] (0.41-0.50 for men and 0.36-0.44 for women).  
Comparisons of the PEths concentrations measured using the three assays (Table 3) have 
shown limits of agreement of less than 33.62%, with no significant differences using 
Wilcoxon signed rank test analyses (p≥0.05) and Bland-Altman analyses (mean differences < 
2.82%, with the zero value included in the 95% CI). Passing-Bablok regressions indicated a 
good overall correlation (R>0.962), no systematic differences (95% CI of the intercept values 
include the zero value) and no proportional differences, although 1 was just not included in 
the 95% CI of the slope in 3 out of 9 comparisons. In literature, agreement between venous 
blood and V-DBS concentrations has been assessed using Bland-Altman analysis for PEth 
18:1/18:1 and PEth 16:0/18:1 [15, 18]. One study showed good agreement, with a mean 
difference of 95.8 ng/mL (RSD=3.0%) and -4.3 ng/mL (RSD=2.9%) for PEth 16:0/18:1 and 
PEth 18:1/18:1, respectively [15]. Another study, despite a limit of agreement of more than 
50%, reported no significant bias (mean -4.5%; RSD=33.8%) for PEth 16:0/18:1 and a good 
correlation (R=0.94) when comparing 281 results obtained from the analysis of venous blood 
and of 3 punches excised from V-DBS [18]. Both studies concluded that PEth 16:0/18:1 and 
18:1/18:1 in V-DBS were a useful tool to monitor alcohol misuse. Our population study not 
only confirms these conclusions, but also extends these to PEth 16:0/16:0, and, importantly, 
demonstrates the agreement between blood and C-DBS. The latter is the most relevant 
comparison, as in real practice, C-DBS will be collected from a fingertip. Thus, the results 
presented here strongly suggest that C-DBS analysis is a valid alternative to venous blood 
analysis for the quantification of PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0. In 
addition, we studied the distribution of PEths within the two groups (inpatients in alcohol 
withdrawal and control volunteers). In 50, 47 and 34 out of the 50 inpatients in alcohol 
withdrawal, PEth 16:0/18:1 (from 16 to more than 2000 ng/mL), PEth 18:1/18:1 (17-307 
ng/mL) and PEth 16:0/16:0 (25-203 ng/mL), respectively, were quantified. PEth 16:0/18:1 
was quantified in 18 out of the 50 control volunteers (13-220 ng/mL), while PEth 18:1/18:1 
(17 ng/mL) was quantifiable in only one. PEth 16:0/16:0 was not present above LLOQ in 
control volunteers. These results suggest that, using the methods presented in this publication, 
only PEth 16:0/18:1 could be used to distinguish inpatients in alcohol withdrawal from 
control volunteers. More sensitive methods are required to search for a cut-off value for PEth 
18:1/18:1 and PEth 16:0/16:0.        
In literature, HPLC-ELSD methods analysing total PEths in blood generally used cut-off 
values between 0.2 and 1 µmol/L [7, 10, 11, 17, 19] to detect alcohol consumption. In 
Sweden, 0.7 µmol/L of total PEths is used as the clinical threshold [7]. These values were 
fixed by the LLOQ of the methods used and are limited to the detection of relatively high 
alcohol consumption (i.e. more than 50 g ethanol per day at an LLOQ of 0.7 µmol/L total 
PEths [17]). For PEth 16:0/18:1, an upper reference value for blood donors (N=200) of 141 
ng/mL (0.2 µmol/L) has been proposed, which provided 5% false positive results and 17 
samples detected as outliers [8]. In addition, two cut-off values for PEth 16:0/18:1 have been 
proposed, one of 700 ng/mL to detect problematic drinking [19] and another of 80 ng/mL to 
detect alcohol consumption (4 drinks daily during 30 days) in patients with liver disease 
(N=222) [37]. This second proposed cut-off value was selected to improve the sensitivity of 
the test (91%), and so provides a lower specificity (77%), which nevertheless can be 
improved up to 90% using a cut-off value of 300 ng/mL [32]. 
In our case, we have calculated a cut-off value of 221 ng/mL in blood to detect chronic and 
excessive alcohol consumption (inpatients on alcohol withdrawal), based on the highest 
sensitivity (86%) which was associated with the absence of false positive results 
(specificity=100%). It is of interest to add that 3 out of the 7 inpatients with PEth 16:0/18:1 
concentrations lower than the chosen cut-off value declared to have ceased their alcohol 
consumption 2-3 weeks before the sampling. Importantly, and lending further support to the 
validity of using C-DBS, is that application of the blood cut-off to the C-DBS and V-DBS 
data yielded the same sensitivity and specificity. 
 
Conclusion 
This report describes the validation of three UHPLC-ESI-MS/MS methods for the 
quantification of PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0 in 30 µL venous blood, 
30 µL V-DBS and 3 punches (3mm) from C-DBS. The calibration curves ranged from 10 
(LLOQ) to 2000 ng/mL for PEth 16:0/18:1, from 10 (LLOQ) to 1940 ng/mL for PEth 
18:1/18:1 and from 19 (LLOQ) to 3872 ng/mL for PEth 16:0/16:0. Our results have 
confirmed the stability of PEths in blood stored at -80°C and have demonstrated that PEth 
16:0/18:1 and PEth 18:1/18:1 were stable in V-DBS at room temperature for up to 6 months. 
The quantification of PEths via the C-DBS method was not significantly influenced by the 
hematocrit, the punch localization or the spot volume. Statistical comparisons (Bland-Altman 
plot, Passing-Bablok regression analysis and Wilcoxon signed rank test) of the measured 
concentrations obtained from venous blood, V-DBS and C-DBS from 100 volunteers 
(alcoholic inpatients and control volunteers) showed good agreement. Furthermore, 
application of a cut-off value of 221 ng/mL for PEth 16:0/18:1 to distinguish between 
inpatients in alcohol withdrawal and control volunteers provided a sensitivity of 86% and no 
false positive results (specificity=100%). To conclude, the developed method for C-DBS can 
be of interest to detect high and chronic alcohol consumption, as it offers distinct advantages 
such as a less invasive blood sample collection, stability during storage and transportation and 
a relatively simple sample preparation before analysis. 
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 Blood and V-DBS methods   
   
Dilution 1  
  
Dilution 2 
(50 µL Dilution 1 in 200 µL Blood) 
Cal-WS (100 µg/mL)     PEth species concentration (ng/ml) 
 STD (µL)  H2O (µL)  16:0/18:1 18:1/18:1 16:0/16:0 
Cal 1 50 Cal-WS  450  2000 1940 3872 
Cal 2 200 Cal 1  200  1000 970 1936 
Cal 3 200 Cal 2  200  500 485 968 
Cal 4 100 Cal 3  100  250 243 484 
Cal 5 100 Cal 3  400  100 97 194 
Cal 6 100 Cal 5  100  50 49 97 
Cal 7 100 Cal 5  400  20 19 39 
Cal 8 100 Cal 7  100  10 10 19 
QCs         
Cal-QC (50 µg/mL)     
QC H 50 Cal-QC  350  1250 1213 2420 
QC M 40 Cal-QC  960  400 388 774 
QC L 100 QC M  700  27 26 52 
Table S4 Dilution table for the whole blood method and for the V-DBS method 
 
C-DBS methods   
   
Dilution 1 
  
Dilution 2 
(10 µL Dilution 1 in 240 µL Blood) 
Cal-WS (250 µg/mL)     PEth species concentration (ng/ml) 
 STD (µL)  H2O (µL)  16:0/18:1 18:1/18:1 16:0/16:0 
Cal 1 50 Cal-WS  200  2000 1940 3872 
Cal 2 100 Cal 1  100  1000 970 1936 
Cal 3 100 Cal 2  100  500 485 968 
Cal 4 50 Cal 3  50  250 243 484 
Cal 5 50 Cal 3  200  100 97 194 
Cal 6 100 Cal 5  100  50 49 97 
Cal 7 50 Cal 5  200  20 19 39 
Cal 8 100 Cal 7  100  10 10 19 
QCs         
Cal-QC (250 µg/mL)     
QC H 30 Cal-QC  210  1250 1213 2420 
QC M 30 Cal-QC  720  400 388 774 
QC L 30 Cal M  420  27 26 52 
Table S5 Dilution table for the C-DBS method 
 Fig. S3 (Left) Influence of the hematocrit on PEths responses measured in low and high QCs. Results are presented as 
mean % bias compared with the reference value (Hct = 0.48). (Right) Influence of the volume on PEths responses 
measured in low and high QCs at three Hct levels. Results are presented as a mean % bias compared with the 
reference value (volume = 35 µL) 
 Fig. S2 (Left) Passing-Bablok regression analyses of PEth species concentrations measured in blood and in V-
DBS. The identity line is indicated using a dotted line. (Right) Bland-Altman analyses of PEth species plotting 
the % difference between blood and V-DBS concentration. The average difference is represented by a solid line, 
the limits of agreement (1.96 SD) by dashed lines and the 95% confidence intervals for the mean and the limits 
of agreement by dotted lines. 
 
Fig. S3 (Left) Passing-Bablok regression analyses of PEth species concentrations measured in V-DBS and in C-
DBS. The identity line is indicated using a dotted line. (Right) Bland-Altman analyses of PEth species plotting 
the % difference between V-DBS and C-DBS concentration. The average difference is represented by a solid 
line, the limits of agreement (1.96 SD) by dashed lines and the 95% confidence intervals for the mean and the 
limits of agreement by dotted lines. 
 
Fig. S4 Concentrations measured (case 3) and LLOQ in whole blood and C-DBS presented with the 
measurement uncertainty (U). Taking into account the measurement uncertainty for the LLOQ, whole blood 
result is considered as positive while C-DBS results is considered as negative. 
 
 
